|Day Low/High||1.76 / 1.85|
|52 Wk Low/High||0.52 / 2.95|
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ocera Therapeutics, Inc.
-- Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right --
Results Expected by Year-End 2017
-- Company Presentation Scheduled for April 4, 2017 at 4:20 PM ET --
Company Presentation Scheduled for March 8, 2017 at 11:20 AM ET
Levi & Korsinsky announces it has commenced an investigation of Ocera Therapeutics, Inc.
Top-line Data Expected in First Quarter 2017
Company Presentation Scheduled for November 16, 2016 at 11:45 AM ET
-- Encouraging Data from NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure --
Company Presentation Scheduled for October 18, 2016 at 8:30 AM PT
Company Presentation Scheduled for September 27, 2016 at 12:00 PM ET
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.